Valuation: Incyte Corporation

Market Cap 22.91B 20.06B 18.52B 17.29B 32.55B 2,166B 33.29B 223B 86.02B 1,068B 86.03B 84.14B 3,709B P/E 2026 *
16.6x
P/E 2027 * 14.4x
Enterprise Value 17.89B 15.66B 14.46B 13.5B 25.42B 1,691B 26B 174B 67.17B 834B 67.18B 65.7B 2,897B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.58x
Free-Float
98.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week+10.61%
Current month+18.52%
1 month+18.52%
3 months+26.98%
6 months+15.48%
Current year+16.09%
1 week 104.49
Extreme 104.49
115.56
1 month 92.18
Extreme 92.18
115.56
Current year 89.25
Extreme 89.25
115.56
1 year 66.83
Extreme 66.83
115.56
3 years 50.27
Extreme 50.27
115.56
5 years 50.27
Extreme 50.27
115.56
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 25/06/2025
Director of Finance/CFO 57 03/05/2026
President 62 04/06/2023
Director TitleAgeSince
Chairman 59 25/06/2025
Director/Board Member 72 19/01/2015
Director/Board Member 64 19/01/2015
Date Insider Type Main position Quantity % Market Cap.
06-07Free

Director

7,753 0.0039%
06-07
FBS Associates LLC
OtherCompany 0 0%
06-07
Baker Bros. Advisors LP
FreeCompany 15,506 0.0078%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%+10.61%+67.71%+85.38% 22.91B
-0.17%+3.15%+21.27%-10.81% 64.28B
+1.93%+6.42%+54.82%+229.54% 57.29B
+7.82%+44.80%+44.80%+44.80% 43.45B
-0.83%+2.21%-52.18%-58.71% 38.02B
+0.28%+8.47%+71.82%-23.22% 31.98B
+3.61%+17.45%+156.63%-42.92% 27.66B
0.00%+4.44%+1.91%+169.93% 17.74B
-0.77%+4.00%+62.54%+123.05% 16.45B
+2.52%+4.48%+60.52%+323.84% 14.1B
Average +1.51%+8.20%+48.98%+84.09% 33.39B
Weighted average by Cap. +1.67%+7.81%+43.63%+65.30%

Financials

2026 *2027 *
Net sales 5.65B 4.94B 4.56B 4.26B 8.02B 534B 8.2B 54.92B 21.2B 263B 21.2B 20.74B 914B 6.22B 5.44B 5.03B 4.69B 8.83B 588B 9.04B 60.48B 23.35B 290B 23.35B 22.84B 1,007B
Net income 1.44B 1.26B 1.16B 1.08B 2.04B 136B 2.09B 13.98B 5.4B 67.03B 5.4B 5.28B 233B 1.67B 1.47B 1.35B 1.26B 2.38B 158B 2.43B 16.28B 6.29B 78.07B 6.29B 6.15B 271B
Net Debt -5.02B -4.39B -4.06B -3.79B -7.13B -475B -7.29B -48.82B -18.85B -234B -18.85B -18.43B -813B -6.87B -6.02B -5.56B -5.19B -9.77B -650B -9.99B -66.86B -25.81B -321B -25.81B -25.25B -1,113B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
29/06/26 US$114.66 +0.80% 1,532,380
26/06/26 US$113.75 +5.78% 3,795,266
25/06/26 US$107.53 -0.86% 1,832,481
24/06/26 US$108.46 +3.89% 1,963,908
23/06/26 US$104.40 +0.71% 1,670,984
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
114.66USD
Average target price
111.27USD
Spread / Average Target
-2.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock